Council Members in this Study Group: 217
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Leading institutions connect with members of this Study Group through GLG
Sanjay RaoMedical Director
Lakeside Eye Clinic![]()
Sanjay Rao, MD, is the Medical Director and Director of Cornea and Refractive Surgery at the Lakeside Eye Clinic in Chicago. He was previously the Director of Cornea and Refractive Surgery at the University of Chicago. He has clinical expertise in diseases...
Gaurav ShahAssociate Professor of Ophthalmology
WASHINGTON UNIVERSITY MEDICAL CENTER![]()
Gaurav Shah, MD, is an Associate Professor of Ophthalmology at the Washington University Medical Center in Missouri. He is a national expert in the care of patients with diabetic retinopathy/diabetic macular edema, age-related macular degeneration, retinal...
Barry SchechterDirector of Corneal and External Diseases
FLORIDA EYE MICROSURGICAL INSTITUTE INC![]()
Barry Schechter, MD, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Dr. Schechter's practice involves diseases of the ocular surface including dry eyes, allergies, infection; the latest in corneal,...
Elizabeth DavisPartner
MINNESOTA EYE CONSULTANTS PA![]()
Elizabeth Davis, MD, FACS, is Clinical Assistant Professor of Ophthalmology at the University of Minnesota. Dr. Davis is also Partner and Medical Director of the Surgery Center at Minnesota Eye Consultants. She is fellowship trained in corneal, cataract,...
President
Ophthalmology Consultants![]()
Andrew Dahl, MD, FACS, FAAO, is the President of Ophthalmology Consultants in New York. He was also Principal Investigator for Hudson Valley Eye Research Foundation and has conducted numerous clinical trials. Dr. Dahl is a board-certified Ophthalmologist/Ophthalmic...
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Lumigan X EU Committee Recomendation
October 27, 2009
EU committee backs marketing approval of Lumigan | www.pharmabiz.com
The Committee for Medicinal Products for Human Use (CHMP) of the European Union has recommended granting a Marketing Authorization for a new version of Allergan's Lumigan (bimatoprost ophthalmic solution). This new version will be marketed as Lumigan-X after approval. Lumigan X offers Allergan a new formulation to compete against generic versions of its glaucoma drug Lumigan after patent protection for Lumigan expires shortly.There will be very limited demand for Lumigan-X.
Tecnis Multifocal Outperforms Competitors
September 20, 2009
Summary of Safety and Effectiveness Data (FDA) | www.fda.gov
The US Clinical Investigation of the Tecnis Multifocal demonstrated 88% complete freedom from glasses at 6 months, and 95% satisfaction at one year. A comparable study of the ReStor lenses, with both 3 and 4 diopter adds, demonstrated 76% freedom from glasses at 4 - 6 months. Despite a one line lower performance at intermediate range for the Tecnis the overall results favor its adoption for providing presbyopia correction after cataract surgery.
AMO Grows Portfolio, Potential with Acquisition of Accommodating Lens Implant
September 3, 2009
Abbott to Acquire Visiogen, Expanding Vision Care Portfolio | www.abbott.com
It was announced today that Abbot Labs intends to acquire Visiogen (Santa Ana, CA) for $400 million in cash. Earlier this year Abbott acquired Advanced Medical Optics, manufacturer of the Tecnis Multifocal IOL and the VISX excimer laser. Visiogen's accommodating IOL, called Synchrony, is designed to deliver improved vision at all distances, potentially eliminating the need for glasses. Visiogen has obtained he CE Mark. FDA approval is pending and is expected in mid 2010.
Tecnis Multifocal FDA Data Shatters the Bifocal Glasses Ceiling
April 1, 2009
Summary of Safety and Effectiveness Data (FDA) | www.fda.gov
The approval of the Tecnis Multifocal IOL represents an exciting new alternative for patients in the United States with cataracts and those presbyopic individuals who desire spectacle independence. With the highest level of subjects who never wear glasses ever reported in an FDA monitored investigation, the Tecnis Multifocal heads to the front of the pack of the multifocal, presbyopia correcting IOLs. The crystalens (B & L, Rochester, NY) remains the only approved accommodative IOL in the United States.
Refractive Cataract Surgery's Holy Grail: Keep it in Sight
March 2, 2009
Lens refilling to restore accommodation | www.sciencedirect.com
The concept of re-filling the empty lens capsule following lens or cataract extraction with an elastic substance that mimics the accommodative function of the youthful human lens remains a captivating concept for researchers. Nishi's review article highlights the progress so far in this direction, as well as the challenges inherent in development of a successful design. These challenges include sealing the capsule to prevent leakage of the injectable material, adjusting the refractive state for emmetropia, allowing adequate accommodative amplitude and preventing capsular opacification.
| Study Group Name | No. Members |
|---|---|
| Ophthalmologists | 1610 |
| Ophthalmologists (US) | 1133 |
| LASIK Surgeons | 186 |
| Corneal and Refractive Ophthalmic Surgeons (US) | 518 |
| Refractive Surgeons (US) | 309 |
| LASIK Surgeons (US) | 143 |
| Refractive Surgeons in Private Practice (US) | 213 |
| Cataract Surgeons (US) | 111 |
November 20, 2006 | San Francisco
GLGi: Intraocular Lenses (IOLs)May 9, 2006 | Chicago
GLGi: OphthalmologyApril 19, 2006 | New York
GLGi: Ophthalmology Grand RoundsLeading Experts in Physicians who Implant Intraocular Lenses have not participated in any GLG webcasts.